Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials. World Health Organization, Geneva, Switzerland, 12-13 February 2009

Vaccine

Volumn 27, Issue 31, 2009, Pages 4079-4089

  Hayden, Frederick G ^a   Howard, Wendy A ^a   Palkonyay, Laszlo ^b   Kieny, Marie Paule ^b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Clinical trials; H5N1; Influenza; Pandemic; Vaccine

Indexed keywords

AF 03; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; AS 03; AVIFLU; DNA VACCINE; EGG DERIVED INACTIVATED VACCINE; HEMAGGLUTININ; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN PROTEIN M2E VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H1N1 VACCINE; INFLUENZA VIRUS A H2N2 VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; INFLUENZA VIRUS A H6N1 VACCINE; INFLUENZA VIRUS A H7N3 VACCINE; INFLUENZA VIRUS A H9N2 VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; PREPANDRIX; Q PAN; RECOMBINANT HEMAGGLUTININ VACCINE; SIALIDASE; UNCLASSIFIED DRUG; VAXFECTIN; VIROSOME VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; CELL FUSION; CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPITOPE MAPPING; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; NASAL DISCOMFORT; NONHUMAN; PANDEMIC; PHARYNGITIS; PRIORITY JOURNAL; SERODIAGNOSIS; SEROLOGY; SINGLE DRUG DOSE; SWITZERLAND; TECHNOLOGY; UNSPECIFIED SIDE EFFECT; VERO CELL; VIRION; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; SWITZERLAND; VACCINES, ATTENUATED; VACCINES, INACTIVATED; WORLD HEALTH ORGANIZATION;

EID: 67349186876     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.059     Document Type: Conference Paper

References (40)

1. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., et al. Phase I and II randomised trials of the safety and immunogenicity od a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26 33 (2008) 4160-4167
2. Nolan T.M., Richmond P.C., Formica N.T., Hoschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26 50 (2008) 6383-6391
3. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
4. Chotpitayasunondh T., Thisyakorn U., Pancharoen C., Pepin S., and Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS ONE 3 (2008) [e4028 Epub]
5. Höschler K., Gopal R., Andrews N., Saville M., Pepin S., Wood J., et al. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza Respir Viruses 1 5-6 (2007) 199-206
6. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 5 (2008) 667-675
7. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., montomoli E., et al. MF59 adjuvanted H5N1 vaccine induces immunologoc memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4 2 (2009) e4384
8. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 359 15 (2008) 1631-1633
9. Schultz V., D'Agosto V., Wack A., Novicki D., Zorn J., and Hennig R. Safety of MF59 adjuvant. Vaccine 26 26 (2008) 3189-3370
10. Girard M., Palkonyay L., and Kieny M.P. Report of the 4th meeting on the Evaluation of pandemic influenza prototype vaccines in clinical trials. World health Organisation, Geneva, Switzerland, 14-15 February. Vaccine 26 (2008) 4975-4977
11. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
12. Rümke H.C., Bayas J.-M., de Juanes J.-R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26 19 (2008) 2378-2388
13. Ehrlich H.J., Müller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 24 (2008) 2573-2584
14. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., and Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4 2 (2007) e59
15. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3 12 (2008) e3942
16. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 3 (2009) 265-273
17. Stelzer-Braid S., Wong B., Robertson P., Lynch G.W., Laurie K., Shaw R., et al. A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies. J Clin Virol 43 2 (2008) 241-243
18. Tang J.W., Ngai K.L., and Chan P.K. Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. J Med Virol 80 11 (2008) 1992-1996
19. Jameson J., Cruz J., Terajima M., and Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162 (1999) 7578-7583
20. Gioia C., Castilletti C., Tempestilli M., Piacentini P., Bordi L., Chiappini R., et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14 1 (2008) 121-128
21. Kreijtz J.H., de Mutsert G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82 11 (2008) 5161-5166
22. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 10 (2008) 3478-3490
23. http://www.who.int/vaccine research/Questions and Answers Nobilon.pdf
24. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappell E., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 199 (2009) 711-716
25. http://www.who.int/vaccine_research/diseases/influenza/meeting_120707/en /index.html
26. Rudenko L., Desheva J., Korovkin S., Mironov A., Rekstin A., Grigorieva E., et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Respir Viruses 2 6 (2008) 203-209
27. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26 42 (2008) 5393-5399
28. de Vries J.J., Bungener L., Ter Veer W., van Alphen L., van der Ley P., Wilschut J., et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 27 6 (2009) 947-955
29. Radosević K., Rodriquez A., Mintardjo R., Tax D., Bengtsson K.L., Thompson C., et al. Antibody and T-cell responses to a virosoaml adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 26 29-30 (2008) 3640-3646
30. Liu W., Zou P., and Chen Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93 2-3 (2004) 131-136
31. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3 (2006) 102
32. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80 2 (2008) 168-177
33. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant haemagglutinin vaccine for H5 influenza in humans. Vaccine 19 13-14 (2001) 1732-1737
34. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106 10 (2009) 3877-3882
35. Temperton N.J., Hoschler K., Major D., Nicolson C., Manvell R., Minh Hien V., et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Respir Viruses 1 3 (2007) 105-112
36. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283 17 (2008) 11382-11387
37. Goji N.A., Nolan C., Hill H., Wolff M., Noah D.L., Williams T.B., et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 198 5 (2008) 635-641
38. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., and Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197 4 (2008) 580-583
39. Stephenson I., Gaines D.R., Wood J.M., and Katz J.M. Comparison of neutralising antibody assays for setection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25 (2007) 4056-4063
40. Puig-Barberà J., Díez-Domingo J., Varea A.B., Chavarri G.S., Rodrigo J.A., Hoyos S.P., et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine I preventing hospitalizations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25 42 (2007) 7313-7321